09:51 AM EST - BriaCell Therapeutics Corp. : Provided a clinical engagement update of its pivotal Phase 3 study of Bria-IMT™ in combination with immune check point inhibitor in metastatic breast cancer (MBC). The study will enroll up to 354 patients randomized 1:1 to the BriaCell combination regimen or physician’s choice and will include a small number (n=50) of patients randomized to Bria-IMT™ monotherapy. BriaCell Therapeutics Corp.
shares T.BCT are trading down $0.06 at $1.28.
